Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label phase 1/2 study of IPN60300 in advanced or metastatic solid tumors
2025-522139-33-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of IPN60300 in Nonhematologic neoplasms (3 arms), sponsored by Ipsen. Primary endpoints: Dose-limiting toxicity rate, Treatment-emergent adverse events and serious adverse events and 1 more. Planned start Dec 2025; status: authorised.
02
Drugs
IPN60300
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-522139-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522139-33-00.